UFPT

UFPT is a genuinely good business: a contract developer/manufacturer of single-use medical devices embedded in the supply chains of top device makers. FY2025 revenue rose 19.5% to $603M and net income 15.8% to $68.3M, while the balance sheet got materially stronger — liabilities fell 19.2%, long-term debt fell 30.5% to $123M, equity grew 23.7% to $424M (L/E just 0.55x), and operating cash flow jumped 38% to $91.9M against only ~$9.7M of capex. ROE of 16.1% on a deleveraging book is healthy. This is not a quality problem.

The problem is the composition of growth and the price paid for it. Management discloses that organic sales growth was only 1.5%; the 2024–2025 acquisitions contributed ~$168.3M of the revenue (vs $73.1M prior year), so virtually all of the headline 19.5% is bought, not earned. Margins also slipped on every line — gross 29.1%→28.3%, operating 16.1%→15.3%, net 11.7%→11.3% — partly from the AJR Labor Issue (an E-Verify-driven workforce turnover that added $6.3M of cost; gross margin would have been 29.3% without it) and from SG&A rising 24.5%. At $263.63 the stock trades at 30.1x FY EPS of $8.75 and 3.4x sales — a full multiple for a company whose underlying organic engine is barely growing and whose margins are drifting the wrong way.